Differential Metabolic Dysregulations in Hepatocellular Carcinoma and Cirrhosis: Insights into Lipidomic Signatures
Rattachement africain : ro. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Hepatocellular carcinoma (HCC), the most common primary liver malignancy, usually develops in patients with cirrhosis, yet the metabolic mechanisms that distinguish the two conditions remain poorly understood. This study aimed to explore metabolic dysregulations in HCC compared with cirrhosis and to identify potential biomarkers, especially lipids, with diagnostic and prognostic value. We prospectively studied 81 patients—41 with HCC and 40 with cirrhosis—using high-resolution UHPLC-QTOF-ESI+-MS to characterize their serum lipidome. Across both groups, 322 metabolites were identified, but their distribution was strikingly different. Patients with HCC showed higher levels of sphingolipids, glycerophospholipids, diglycerides, sterols, and certain fatty acids, reflecting tumor-related metabolic rewiring. In contrast, cirrhotic patients had increased D-glucose, 5-hydroxymethyluracil, lysophospholipids, acylcarnitines, and specific fatty acid derivatives. Several lipids, such as CerPE(d16:2/24:1(2OH)), SM(d18:0/14:0), PA(36:6), and GlcCer(d18:1/12:0), displayed excellent discriminative accuracy, highlighting their role as putative biomarkers. These findings underscore the importance of lipid metabolic reprogramming in HCC, characterized by membrane remodeling, energy adaptation, and oxidative stress resistance. Integrating lipidomic profiling into clinical practice could improve early detection and risk stratification in cirrhotic patients. Larger, multicenter studies are needed to validate these biomarkers and assess their therapeutic implications.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Differential Metabolic Dysregulations in Hepatocellular Carcinoma and Cirrhosis: Insights into Lipidomic Signatures
- Date Crossref
- 10/11/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Iuliu Hațieganu University of Medicine and Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Institutul Regional de Gastroenterologie Prof. Dr. Octavian Fodor pays non établi dans la noticeÉtablissement de santé
-
“Iuliu Hațieganu” University of Medicine and Pharmacy Department of Surgery-Practical Skills pays non établi dans la noticeUniversité ou école supérieure
-
“Prof. Dr. Octavian Fodor” Regional Institute of Gastroenterology and Hepatology pays non établi dans la noticeStructure de recherche
-
"Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology pays non établi dans la noticeStructure de recherche
-
Center for Applied Biotechnology Biodiatech pays non établi dans la noticeInstitution
Iuliu Hațieganu University of Medicine and Pharmacy, Institutul Regional de Gastroenterologie Prof. Dr. Octavian Fodor et Department of Surgery-Practical Skills — “Iuliu Hațieganu” University of Medicine and Pharmacy, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.